New Delhi: The government has revised its covid guidelines and has stated that there is no evidence of benefit from injectable steroids in coronavirus disease (Covid-19) patients who do not require oxygen supplementation or in continuation, after discharge. AIIMS, the Indian Council of Medical Research (ICMR), and Covid-19 National Task Force and Joint Monitoring Group jointly issued a clinical. In that clinical, they have against warned that anti-inflammatory therapy can lead to a risk of secondary infection like invasive mucormycosis, or ‘black fungus’.
“There is no evidence for benefit for injectable steroids in those not requiring oxygen supplementation, or on continuation after discharge anti-inflammatory or immunomodulatory therapy (such as steroids) can have a risk of secondary infection such as invasive mucormycosis when used too early, at higher doses or for longer than required,” the guidelines stated.
Under the anti-inflammatory or immunomodulatory therapy, the guidelines say, “Injection Methylprednisolone 0.5 to 1 mg/kg in two divided doses or equivalent dose of dexamethasone can be given usually for a duration of 5 to 10 days” in Covid-19 patients. The medicine can be administered orally if the condition of the patient is stable and/or improving.
Adult Covid-19 patients have been divided into three categories of mild, moderate, and severe disease based on upper respiratory tract symptoms and breathlessness. The government-recommended treatments do not include medicines like ivermectin, favipiravir, and Doxycycline. Antivirals like Molnupiravir and monoclonal antibodies are also not included in the guidelines.
Government warns against tuberculosis and other conditions. It has advised people to investigate for tuberculosis and other conditions if cough persists for more than 2-3 weeks after testing positive for Covid-19.
According to the guidelines, people aged 60 and above with cardiovascular disease, hypertension, and CAD Diabetes mellitus and other immunocompromised states (such as HIV), active tuberculosis, chronic lung/kidney/liver disease, cerebrovascular disease, and obesity are at high risk for severe disease or mortality.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
